Kapîcîoglu S, Sentürk O, Ilgün K, Ovali E
Blacksea Technical University, School of Medicine, Department of Internal Medicine, Trabzon, Turkey.
Hepatogastroenterology. 1998 Mar-Apr;45(20):420-3.
BACKGROUND/AIMS: In this study we investigated the effect of the long-acting somatostatin analog octreotide (SMS 201-995) plus calcium channel blocker (Verapamil) on gallbladder contraction.
Fourty healthy volunteers participated in this study. Gallbladder volumes were measured by ultrasonography. After recording the baseline measurement, the volunteers received either saline (n:10), or SMS 201-995 100 B microgram subcutaneously (s.c.) (n:10) or verapamil 80 mg peroral (po) (n:10), or verapamil plus SMS 201-995 (n:10). Two hours later the gallbladder volumes were rescanned in 15 min intervals for 60 min. At the end all volunteers received standard liquid test meal (ensure 250 Cal/250 ml) and scans were again performed for one hour.
The mean baseline gallbladder volume was 18.6 +/- 5.2 ml in all groups. The gallbladder volumes in the placebo group were 18.6 +/- 5.2 to 19.0 +/- 10.2 ml. In this group, after administration of test meal decreased the mean gallbladder volume to 14.3 +/- 7.5 to 8.4 +/- 5.8 ml, but these values were not significantly different from the baseline values. In the verapamil group the volumes increased from 18.6 +/- 5.2 to 28.5 +/- 9.7 to 30.8 +/- 11.6 ml. These values were significantly different from the baseline and the control group (p < 0.05). In this group, post-prandial mean volumes decreased to baseline in 30 min, but these values were higher than in the placebo group (p < 0.01). Verapamil-induced fasting the gallbladder relaxation was totally abolished to the placebo value by SMS 201-995. In verapamil plus SMS 201-995 and SMS 201-995 alone groups, the fasting and post-prandial volumes did not change when compared to the baseline value, but post-prandial volumes were higher than the placebo (p < 0.01).
These results suggest that verapamil-induced gallbladder relaxation was totally abolished by SMS 201-995.
背景/目的：在本研究中，我们调查了长效生长抑素类似物奥曲肽（SMS 201-995）加钙通道阻滞剂（维拉帕米）对胆囊收缩的影响。
40名健康志愿者参与了本研究。通过超声测量胆囊体积。记录基线测量值后，志愿者分别接受生理盐水（n = 10）、皮下注射100μg SMS 201-995（n = 10）、口服80mg维拉帕米（n = 10）或维拉帕米加SMS 201-995（n = 10）。两小时后，每隔15分钟对胆囊体积进行重新扫描，共60分钟。最后，所有志愿者接受标准液体试验餐（安素250千卡/250毫升），并再次进行一小时扫描。
所有组的平均基线胆囊体积为18.6±5.2毫升。安慰剂组的胆囊体积为18.6±5.2至19.0±10.2毫升。在该组中，给予试验餐后，平均胆囊体积降至14.3±7.5至8.4±5.8毫升，但这些值与基线值无显著差异。在维拉帕米组中，体积从18.6±5.2增加到28.5±9.7再到30.8±11.6毫升。这些值与基线和对照组有显著差异（p<0.05）。在该组中，餐后平均体积在30分钟内降至基线，但这些值高于安慰剂组（p<0.01）。维拉帕米诱导的空腹胆囊松弛被SMS 201-995完全消除至安慰剂值。在维拉帕米加SMS 201-995组和单独使用SMS 201-995组中，与基线值相比，空腹和餐后体积没有变化，但餐后体积高于安慰剂组（p<0.01）。
这些结果表明，维拉帕米诱导的胆囊松弛被SMS 201-995完全消除。
